BrainStorm Cell Therapeutics is a biotechnology company focused on developing and commercializing innovative cellular therapies for neurodegenerative diseases. Their lead product, NurOwn®, is a stem cell-based therapy that uses autologous mesenchymal stem cells (MSCs) derived from a patient's bone marrow. These cells are engineered to secrete neurotrophic factors, which promote the survival and regeneration of damaged nerve cells. BrainStorm is committed to advancing treatments for diseases such as Amyotrophic Lateral Sclerosis (ALS), multiple sclerosis (MS), and other neurological disorders with high unmet medical needs. The company aims to provide hope for patients by pioneering new approaches to regenerative medicine, improving quality of life, and potentially altering the course of these devastating diseases.